Literature

Literature for TECHNOZYM^®ADAMTS-13 Activity chromogen

Posters Etlington J.. et al. ADAMTS-13 is a risk factor for MI, Stroke, and Vascular Death in the Oxford Vascular Study ASH 2008
Kato S. et al. Monoclonal antibodies to a VWF-A2 decapeptide with the C-terminal residue Tyr1605, generated by ADAMTS13 cleavage, develop a highly sensitive ELISA for ist activity and characterize Upshaw-Schulman syndrome ASH 2006
Literature Ferrari S. et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity Blood, 1. April 2007, Vol. 109, No. 7: 2815-2822
Ulinski T. et al. From Humoral Rejection to Generalized Thrombotic Microangiopathy - Role of Acquired ADATS13 Deficiency in a Renal Allograft Recipient American Journal of Transplantation 2006; 6: 3030-3036
Luken B. M. et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura Journal of Thrombosis and Haemostasis, 4: 2355-2364
Miyata T, Kokame K, Banno F. Measurement of ADAMTS13 activityand inhibitors. Curr Opin Hematol. 2005 Sep;12(5):384-9.
Kokame K, Nobe Y, Kokubo Y et al. FRETS-vWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J Haematol. 2005 Apr; 129(1):93-100.
Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem. 2005 Jun 10;280(23):21773-8.
Veyradier A.. and Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. Journal of Thrombosis and Haemostasis, 3: 2420?2427
Klaus C, Plaimauer B, Studt JD et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103:4514-4519.
Sadler JE, Moake JL, Miyata T, George JN. Recent advances in Thrombotic Thrombocytopenic Purpura. Hematol. 2004 407-423
Kokame K, Matsumoto M, Fumimura Y et al. vWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2004 Jan 15;103(2):607-12
Fontana S, Hovinga JA, Studt JD et al. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol. 2004;41:48-59.
Furlan M. et al. Proteolytic cleavage of von Willebrand factor by prevents uninvited clumping of blood platelets. J Thromb Haemost 2004; 2: 150-09
Tsai H.-M. et al. A journey from sickle cell anemia to ADAMTS13. J Thromb Haemost 2004; 2: 1510-14
Moake J.L. et al. Defective processing of unusually large von Willebrand factor multimers and thrombotic thrombocytopenic purpura. J Thromb Haemost 2004; 2: 1515-21
Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A. 2002;99: 11552-11554.
Dong J. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002 100(12) 4033-4039.
Zheng et al. Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura. J.Biol. Chem. 2001, 278(44)